CD44 in maligant disorders

Current Topics in Microbiology and Immunology

Volumn 213 I, Issue , 1996, Pages 270-285

  Gunthert, U ^a  

^a BASEL INSTITUTE FOR IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN;

CARCINOGENESIS; HUMAN; INFLAMMATION; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD44; CELL ADHESION; GENES; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MICE; MODELS, MOLECULAR; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA SPLICING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4243076728     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-61107-0_16     Document Type: Article

References (93)

1. Bartolazzi A, Jackson DG, Bennett K, Aruffo A, Dickinson R, Shields J, Whittle N, Stamenkovic I (1995) Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. J Cell Sci 108 1723-1733
2. Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, Stamenkovic I, Plowman G, Aruffo A (1995) CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 128 687-698
3. Bracke ME, van Roy FM, Mareel MM (1996) The E-cadherin/catenin complex in invasion and metastasis Curr Top Microbiol Immunol 2131: 123-162
4. Brown TA, Bouchard T, St John T, Wayner E, Carter WG (1991) Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons J Cell Biol 113: 207-221
5. Christiansen H, Sahin K, Berthold F, Hero B, Terpe H-J, Lampert F (1995) Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer 31A: 541-544
6. Combaret V, Lasset C, Frappaz D, Bouvier R, Thiesse P, Rebillard A-C, Philip T, Favrot MC (1995) Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. Eur J Cancer 31A: 545-549
7. Cooper DL, Dougherty GJ (1995) To metastasize or not? Selection of CD44 splice sites. Nat Med 1: 635-637
8. Dall P, Heider K-H, Sinn H-P, Skroch-Angel P, Adolf G, Kaufmann M, Herrlich P (1995) Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 60: 471-477
9. Diamond MS, Springer TA (1994) The dynamic regulation of integrin adhesiveness. Curr Biol 4: 506-517
10. Droll A, Dougherty ST, Chiu RK, Dirks JF, McBride WH, Cooper DL, Dougherty GJ (1995) Adhesive interactions between alternatively spliced CD44 isoforms. J Biol Chem 270: 11567-11573
11. East JA, Hart IA (1993) CD44 and its role in tumour progression and metastasis. Eur J Cancer 29A 1921-1922
12. Finke LH, Terpe H-J, Zörb C, Haensch W, Schlag PM (1995) Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 345 583
13. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A, Simmons DL (1994) Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 54: 4539-4546
14. Friedrichs K, Kügler G, Franke F, Terpe H-J, Arlt J, Regidor P-A, Günthert U (1995a) CD44 isoforms in prognosis of breast cancer. Lancet 345: 1237
15. Friedrichs K, Franke F, Lisbon B-W, Kügler G, Gille J, Terpe H-J, Hölzel F, Maass H, Günthert U (1995b) CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55: 5424-5433
16. Fujimoto K, Ichimori Y, Kakizoe T, Okajima E, Sakamoto H, Sugimura T, Terada M (1991) Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Comm 180: 386-392
17. Gallagher JT (1992) The protein and proteoglycan guises of Hermes/CD44. Glycobiology 2: 93-94
18. Günthert U (1993) CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 184: 47-63
19. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65 13-24
20. Günthert U, Stauder R, Mayer B, Terpe H-J, Finke L, Friedrichs K (1995) Are CD44 variant isoforms involved in human tumor progression? Cancer Surv 24: 19-42
21. Haegel H, Tölg C, Hofmann M, Ceredig R (1993) Activated mouse astrocytes and T cells express similar CD44 variants. Role of CD44 in astrocyte/T cell binding. J Cell Biol 122: 1067-1077
22. Hall CL, Yang B, Yang X, Zhang S, Turley M, Samuel S, Lange LA, Wang C, Curpen GD, Savani RC, Greenberg AH, Turley EA (1995) Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 82: 19-28
23. Haynes BF, Liao HX, Patton KL (1991a) The transmembrane hyaluronate receptor (CD44) multiple functions, multiple forms. Cancer Cells 3: 347-350
24. Haynes BF, Hale LP, Patton KL, Martin ME, McCallum RM (1991b) Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Arthritis Rheum 34: 1434-1443
25. Herrlich P, Zöller M, Pals S, Ponta H (1993a) CD44 splice variants: metastases meet lymphocytes. Immunol Today 14: 395-399
26. Herrlich P, Rudy P, Hofmann M, Arch R, Zöller M, Zawadzki V, Tölg C, Hekele A, Koopman G, Pals S, Heider K-H, Steeman J, Ponta H (1993b) CD44 and splice variants of CD44 in normal differentiation and tumor progression In: Hemler ME, Mihich E (eds) Cell adhesion molecules Plenum, New York, pp 265-288
27. Hofmann M, Rudy W, Zöller M, Tölg C, Ponta H, Herrlich P, Günthert U (1991) CD44 splice variants confer metastatic behaviour in rats homologous sequences are expressed in human tumor cell lines Cancer Res 51: 5292-5297
28. Hofmann M, Rudy W, Günthert U, Zimmer SG, Zawadzki, Zöller M, Lichtner RB, Herrlich P (1993) A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res 53 1516-1521
29. Hong R-L, Lee WJ, Shun CT, Shu JS, Chen YC (1995a) Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas Oncology 52: 334-339
30. Hong R-L, Pu Y-S, Hsieh T-S, Chu J-S, Lee W-J (1995b) Expressions of E-cadherin and exon v6 containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol 153: 2025-2028
31. Hudson DL, Sleeman J, Watt FM (1995) CD44 is the major peanut lectin-binding glycoprotein of human epidermal keratinocytes and plays a role in intercellular adhesion. J Cell Sci 108: 1959-1970
32. Isacke CM (1994) The role of the cytoplasmic domain in regulating CD44 function. J Cell Sci 107: 2353-2359
33. International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 987-994
34. Jackson DG, Bell JI, Dickinson R, Timans J, Shields J, Whittle N (1995) Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the V3 exon. J Cell Biol 128: 673-685
35. Katoh S, Zheng Z, Oritani K, Shimozato T, Kincade PW (1995) Glycosylation of CD44 negatively regulates its recogonition of hyaluronan. J Exp Med 182: 419-429
36. Kaufmann M, Heider K-H, Sinn H-P, von Minckwitz G, Ponta H, Herrlich P (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345: 615-619
37. Kelleher D, Murphy A, Hall N, Omary MB, Kearns G, Long A, Casey EB (1995) Expression of CD44 on rheumatoid synovial fluid lymphocytes. Ann Rheum Dis 54: 566-570
38. Kincade PW (1993) Cell adhesion mechanisms utilized for lympho-hematopoiesis. In: Shimizu Y (ed) Lymphocyte adhesion molecules. Landes, Austin, pp 249-279
39. Kincade PW, He Q, Ishihara K, Miyake K, Lesley J, Hyman R (1993) CD44 and other cell interaction molecules contributing to B lymphopoiesis. Curr Top Microbiol Immunol 184: 215-222
40. Koopman G, Griffioen AW, Ponta H, Herrlich P, van den Berg F, Manten-Horst E, Pals ST (1993a) CD44 splice variants: expression on lymphocytes and in neoplasia Res Immunol 144: 750-754
41. Koopman G, Heider K-H, Horst E, Adolf GR, van den Berg F, Ponta H, Herrlich P, Pals ST (1993b) Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 177: 897-904
42. Koretz K, Möller P, Lehnert T, Hinz U, Otto HF, Herfarth C (1995) Effect of CD44v6 on survival in colorectal carcinoma. Lancet 345: 327-328
43. Krishnan R, Kireta S, Carter JK, Grooby WL, Rao MM, Russ GR (1995) Expression of alternatively spliced CD44 mRNA in sheep renal allografts. Transplant Proc 27: 2170-2171
44. Labarriere N, Piau JP, Otry C, Denis M, Lustenberger P, Meflah K, Le Pendu J (1994) H-blood group antigen carried by CD44v modulates tumorigenicity of rat colon carcinoma cells. Cancer Res 54: 6275-6281
45. Lazaar AL, Puré E (1995) CD44: a model for regulated adhesion function Immunologist 3: 19-25
46. Lesley J, Hyman R, Kincade PW (1993) CD44 and its interactions with the extracellular matrix Adv Immunol 54: 271-335
47. Lesley J, English N, Perschi A, Gregoroff J, Hyman R (1995) Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation J Exp Med 182: 431-437
48. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Günthert U (1994) Expression and modulation of CD44 variant isoforms in humans J Cell Biol 124: 71-82
49. Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildberg FW, Funke I, Johnson JP (1993) De-novo expression of CD44 and survival in gastric cancer. Lancet 342: 1019-1022
50. Mikecz K, Brennan FR, Kim JH, Giant TT (1995) Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murme arthritis. Nat Med 1: 558-563
51. Moll J, Sleeman J, Kondo K, Hekele A, Plug R, Sherman L, Schmidt A, Zöller M, Horst E, Ponta H, Herrlich P, Pals St (1994) Analysis of molecular functions of the tumor metastasis promoting surface molecule CD44v4-v7 using transgenic mice in: Hirohashi S, Moses HL, Ruoslahti E, Sugimura T, Takeichi M, Terada M (eds) Molecular and cellular basis for cell to cell interaction: its significance in cancer. Princeton Scientific, Princeton, pp 142-151
52. Mulder JWR, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJA, Pals ST (1994) Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins Lancet 344: 1470-1472
53. Mulder JWR, Wielenga VJM, Polak MM, van den Berg FM, Adolf GR, Herrlich P, Pals ST, Offerhaus GJA (1995) Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. Gut 36: 76-80
54. Nanus DM, Schmitz-Dräger BJ, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C, Albino AP, Reuter VE (1993) Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 85: 1597-1599
55. Nguyen M, Watanabe H, Budson AE, Richte JP, Hayes DF, Folkman J (1994) Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86: 356-361
56. Pals ST, Koopman G, Griffioen A, Ponta H, Herrlich P, van den Berg F, Horst E (1993a) CD44, a variety of isoforms with functions in cell adhesion and tumor metastasis. In: Shimizu Y (ed) Lymphocyte adhesion molecules Landes, Austin, pp 135-150
57. Pals ST, Koopman G, Heider KH, Griffioen A, Adolf GR, van den Berg F, Ponta H, Herrlich P, Horst E (1993b) CD44 splice variants: expresssion during lymhpocyte activation and tumor progression. Behring Inst Mitt 92: 273-277
58. Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A (1993) Identification of hyaluronic acid binding sites in the extracellular domain of CD44 J Cell Biol 122: 257-264
59. Perschl A, Lesley J, English N, Trowbridge I, Hyman R (1995) Role of CD44 cytoplasmic domain in hyaluronan binding Eur J Immunol 25: 495-501
60. Ponta H, Sleeman J, Herrlich P (1994) Tumor metastasis formation: cell-surface proteins confer metastasis-promoting or -suppressing properties. Biochim Biophys Acta 1198: 1-10
61. Ponta H, Hekele A, Heider K-H, Kaufmann M, von Minckwitz G, Sinn H-P, Pals S, Wielenga VJM, Herrlich P (1995) Relevance of CD44 variant epitopes for diagnosis and therapy of human breast cancer. In: Jonat W (ed) Contribution to oncology. Karger, Basel (in press)
62. Ristamaki R, Hoensuu H, Söderström K-O, Jalkanen S (1995) CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis. J Pathol 176: 259-267
63. Ristamäki R, Joensuu H, Jalkanen S (1996) Does soluble CD44 reflect the clinical behavior of human cancer? Curr Top Microbiol Immunol 213 111: 139-150
64. Rosenberg WMC, Prince C, Kaklamanis L, Fox SB, Jackson DG, Simmons DL, Chapman RW, Trowell JM, Jewell DP, Bell JI (1995) Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease. Lancet 345: 1205-1209
65. Rudy W, Hofmann M, Schwartz-Albiez R, Zöller M, Heider KH, Ponta H, Herrlich P (1993) The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants each one individually suffices to confer metastatic behavior Cancer Res 53: 1262-1268
66. Ruiz P, Günthert U (1995) The cellular basis of metastasis. World J Urol (in press)
67. Ruiz P, Schwärzler C, Günthert U (1995) CD44 isoforms during differentiation and development. Bioessays 17: 17-24
68. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horvak I (1993) Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261
69. Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, Herrlich P, Matzku S, Zöller M (1993) Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177: 443-455
70. Sherman L, Sleeman J, Herrlich P, Ponta H (1994) Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression Curr Opin Cell Biol 6: 726-733
71. Sherman L, Sleeman J, Dall P, Hekele A, Moll J, Ponta H, Herrlich P (1996) The CD44 proteins in embryonic development and in cancer Curr Top Microbiol Immunol 2131: 249-269
72. Sleeman J, Moll J, Sherman L, Dali P, Pals ST, Ponta H, Herrlich P (1995) The role of CD44 splice variants in human metastatic cancer. Ciba Found Symp 189: 142-156
73. Stauder R, Günthert U (1995) CD44 isoforms - impact on lymphocyte activation and differentiation. Immunologist 3: 78-83
74. Stauder R, Eisterer W, Thaler J, Günthert U (1995) CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor Blood 85: 2885-2899
75. Störkel S, Thoenes W, Jacobi GH, Lippold R (1989) Prognostic parameters in renal cell carcinoma - a new approach. Eur Urol 16: 416-422
76. Strober W, Ehrhardt RO (1993) Chronic intestinal inflammation an unexpected outcome in cytokine or T cell receptor mutant mice. Cell 75: 203-205
77. Sy MS, Guo YJ, Stamenkovic I (1991) Distinct effects of two CD44 isofoms on tumor growth in vivo. J Exp Med 174: 859-866
78. Sy MS, Guo YJ, Stamenkovic I (1992) Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein J Exp Med 176: 623-627
79. Sy M-S, Liu D, Schiavone R, Ma J, Mori H, Guo Y (1996) Interactions between CD44 and hyaluronic acid their roles in tumor growth and metastasis. Curr Top Microbiol Immunol 213 111: 113-137
80. Tanabe KK, Saya H (1994) The CD44 adhesion molecule and metastasis Crit Rev Oncog 5: 201-212
81. Tanaka Y, Adams DH, Shaw S (1993) Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes Immunol Today 14: 111-115
82. Tarin D, Matsumura Y (1993) Deranged CD44 gene activity in malignancy J Pathol 171: 249-250
83. Terpe H-J, Stark H, Prehm P, Günthert U (1994a) CD44 variant isoforms are preferentially expressed in basal epithelia of non-malignant human fetal and adult tissues. Histochemistry 101: 79-89
84. Terpe H-J, Koopman R, Imhof BA, Günthert U (1994b) Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high grade malignant lymphomas. J Pathol 174: 89-100
85. Terpe H-J, Christiansen H, Gonzales M, Berthold F, Lampert F (1995a) Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Eur J Cancer 31A: 549-552
86. Terpe H-J, Störkel S, Zimmer U, Anquez V, Fischer C, Pantel K, Gunthert U (1995) Expression of CD44 isoforms in renal cell tumors, positive correlation to tumor progression. Am J Pathol (in press)
87. Thoenes W, Störkel S, Rumpelt HJ (1986) Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). Pathol Res Pract 181: 125-143
88. Underhill C (1992) CD44: the hyaluronan receptor. J Cell Sci 103: 293-298
89. Yang B, Yang BL, Savani RC, Turley EA (1994) Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J 13: 286-296
90. Zheng Z, Katoh S, He Q, Oritani K, Miyake K, Lesley J, Hyman R, Hamik A, Parkhouse RME, Farr AG, Kincade PW (1995) Monoclonal antibodies to CD44 and their influence on hyaluronan recognition. J Cell Biol 130: 485-495
91. Zöller M (1995) CD44 variant expession, lymphocyte homing and lymphogenic metastasis In: Adhesion molecules and cell signalling, biology and clinical applications, vol 1 Raven, New York, pp 201-218
92. Zöller M (1996) Joint features of metastasis formation and lymphocyte maturation and activation. Curr Top Microbiol Immunol 213 1: 215-247
93. Zöller M, Kaufmann M (1994) CD44 and metastasis Onkologie 17: 114-122